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ABSTRACT
Shigella flexneri is an enteropathogen responsible
for severe dysentery in humans. VirF is a key
transcriptional regulator that activates the expres-
sion of the downstream virulence factors required
for cellular invasion and cell-to-cell spread of this
pathogen. There are several environmental factors
that induce the translation of VirF including tem-
perature, pH, osmolarity and post-transcriptional
RNA modification. Durand and colleagues (vacC,
a virulence-associated chromosomal locus of
Shigella flexneri, is homologous to tgt, a gene
encoding tRNA-guanine transglycosylase of
Escherichia coli K-12. J. Bacteriol., 176, 4627–4634)
have demonstrated a correlation between VirF and
tRNA-guanine transglycosylase (TGT), which cata-
lyzes the exchange of the hypermodified base
queuine for the guanine in the wobble position of
certain tRNAs. They characterized tgt- mutant
S. flexneri strains in which the translation of VirF is
markedly reduced and the bacteria are unable to
invade host cells. Although the function of TGT is
to modify tRNA, we report that the virF mRNA is
recognized by the Escherichia coli TGT (99% identity
to the S. flexneri TGT) in vitro. Further, we show that
this recognition results in the site-specific modifica-
tion of a single base in the virF mRNA. In the context
of previous reports that small molecule binding
motifs (‘riboswitches’) in mRNAs modulate mRNA
conformation and translation, our observations
suggest that TGT may modulate the translation
of VirF by base modification of the VirF
encoding mRNA.
INTRODUCTION
The occurrence of non-canonical nucleosides in RNA has
been well-characterized (1–4), with  100 modiﬁed bases
having been found in transfer RNA (tRNA) alone (5).
Modiﬁcations occur at the post-transcriptional level,
where some modiﬁcations are more simple chemical
transformations (e.g. methylation) and still others are
more complex (e.g. transglycosylation). One enzyme that
performs a complex RNA modiﬁcation (hypermodi-
ﬁcation) is tRNA-guanine transglycosylase (TGT, EC
2.4.2.29), catalyzing the exchange of the modiﬁed base
queuine for the anticodon loop wobble position guanine
in eukaryl and eubacterial tRNA
Asp, Asn, His, Tyr (6). The
proposed biochemical pathway for queuine incorporation
in eubacterial tRNA is shown in Figure 1.
Although not yet fully understood, it is known that four
genes are involved in the eubacterial biosynthesis of the
queuine precursor, preQ1 (7). PreQ1 is incorporated into
the tRNA by TGT (8). Two subsequent enzymes convert
preQ1 to queuine in the tRNA (8). In contrast, eukaryl
organisms acquire queuine from external routes such as
diet, and this heterocyclic base is incorporated directly by
the eukaryl TGT (9,10).
TGT plays a vital role in the pathogenesis of shigellosis
(11), a disease that causes severe dysentery in humans. The
pathogenic strain, Shigella ﬂexneri, infects the cells of the
human gastrointestinal tract following evasion of the host
immune system defense mechanisms, such as the engulf-
ment of foreign substances by macrophages. Shigella is
able to escape from the macrophage endosome via the
expression of certain virulence factors (Figure 2). There
are several bacterial genes (including IcsA, IpaB, IpaC and
IpaD) that mediate this escape as well as cell-to-cell spread
of the organism (12). VirF, encoded on the primary
pathogenicity island of Shigella, is a potent transcriptional
regulator of the AraC family that regulates the expression
of these virulence factors (Figure 2) (13,14).
There are several environmental factors that promote
the expression of VirF, including oxygen and iron
limitation, temperature, pH, osmolarity and post-
transcriptional RNA modiﬁcation (15). Durand and
Bjo ¨ rk (11) have demonstrated a positive correlation
between VirF and TGT by characterizing a mutant
Shigella ﬂexneri strain with an inactivated tgt gene
(termed vacC). In this mutant, the translation of VirF
was markedly reduced whereas the levels of virF mRNA
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unable to invade host cells. In addition, when transformed
with a plasmid containing a functional Shigella tgt gene,
restoring queuine modiﬁcation, the Shigella mutants
exhibited both restored VirF expression and virulence,
thus demonstrating a positive connection between virF
mRNA translation and the presence of active TGT (and
presumably queuine modiﬁcation).
The role of modiﬁed nucleosides in RNA structure and
stability has been well-studied (16–18). Agris and Brown
(19) have identiﬁed key interactions between modiﬁed
nucleosides and magnesium ions essential to the secondary
structure of tRNA, in addition to facilitating key
RNA–protein interactions. Mandal et al. (20,21) have
characterized binding of small molecules and metabolites
to RNA motifs termed ‘riboswitches’. Riboswitches are
structural motifs in mRNAs [sometimes in the 50
untranslated region (UTR) and extending into the start
of the open reading frame] that can exist in at least two
stable conformations. One of these conformations is
stabilized by binding to a small molecule, thus altering
the equilibrium between the conformations. One confor-
mation supports translation of the protein while with the
other conformation, translation is blocked. In this way,
binding of the small molecule changes the conformation of
the RNA and modulates its translation. In addition to the
50 UTR of prokaryotic mRNAs, riboswitches have also
been found in the 30 UTR and introns in several
eukaryotic species (22). Interestingly, the Breaker lab
has just reported the discovery of a riboswitch that
responds to the queuine precursor, preQ1 and appears to
regulate the expression of the four genes that are involved
in preQ1 biosynthesis (23). It certainly seems possible
that base modiﬁcation of an mRNA could modulate
a similar conformational change. It therefore is feasible
that such a control mechanism for gene expression might
be involved in regulating the expression of virulence
factors in pathogenic organisms, as is apparently seen
with VirF.
The incorporation of modiﬁed nucleosides has been
characterized more fully for tRNA (and some other
RNAs, e.g. rRNA and snRNA), than for mRNA
(5,24,25). The most common example of post-
transcriptional processing in mRNA is the eukaryotic
7-methylguanosine 50 cap structure, which aids in
the binding to the small ribosomal subunit and is essential
for the eﬃcient synthesis of eukaryotic proteins (26–28).
To date, the only known function of TGT is to catalyze
the modiﬁcation of tRNA with queuine. Previous work
has shown that the eubacterial TGT will recognize a U-G-
U sequence in the loop of an RNA hairpin structure that
corresponds to the anticodon stem–loop of its cognate
tRNAs (29,30). The eubacterial TGT will also recognize a
U-G-U containing hairpin in the context of a dimeric form
of a cognate tRNA (31).
It is conceivable that an mRNA may also be modiﬁed
directly by TGT, provided the mRNA contained
the appropriate recognition elements. An examination of
the sequence of virF mRNA for the presence of U-G-U
sequences revealed six unique U-G-U sites (Figure 3).
Mfold analysis of the regions surrounding each of these
U-G-U sequences reveal that nucleotides 410–433 could
possibly fold into a hairpin structure with the U-G-U
sequence in a position in a loop that is analogous to
the anticodon loop of TGT-cognate tRNAs.
As a ﬁrst step towards probing the possibility that TGT
may modulate the translation of VirF via modiﬁcation of
the virF mRNA, Michaelis–Menten kinetic analyses were
conducted to probe this modiﬁcation by TGT in vitro.W e
report that the Escherichia coli TGT, which has 99%
sequence identity to the S. ﬂexneri TGT, does indeed
recognize the virF mRNA as a substrate in vitro. Further,
we show that this recognition results in the site-speciﬁc
modiﬁcation of a single base in the virF mRNA.
Figure 1. Proposed biochemical pathway for queuine incorporation in
eubacterial and eukaryl tRNA.
Figure 2. Schematic representation of Shigella pathogenesis. The
invasion of the intestinal mucosal cells by S. ﬂexneri is regulated by
a number of virulence factors, including the transcriptional regulator,
VirF. The VirF protein then activates the transcription of downstream
virulence factors under the proper environmental conditions for
invasion. Durand and colleagues (35) have shown that TGT is linked
to the eﬃcient translation of the VirF protein. Figure adapted from one
provided by Prof. Ruth Brenk, University of Dundee.
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Reagents
Unless otherwise speciﬁed, all reagents were ordered from
Sigma or Aldrich. DNA oligonucleotides, agarose, dithio-
threitol (DTT), T4 DNA ligase and DNA ladders were
ordered from Invitrogen. All restriction enzymes and
Vent DNA polymerase were ordered from New
England Biolabs. The ribonucleic acid triphosphates
(NTPs) and pyrophosphatase were ordered from Roche
Applied Sciences. The deoxyribonucleic acid triphosphates
(dNTPs) were ordered from Promega. Low-melting
Seaplaque agarose was ordered from Cambrex. Gelase
TM
Enzyme Prep, MasterAmp
TM High Fidelity RT–PCR Kit,
and Scriptguard
TM RNase Inhibitor were ordered from
Epicentre. Epicurian coli XL2-Blue ultracompetent cells
were ordered from Stratagene. Amicon Ultra Centrifugal
Filter Devices were ordered from Millipore. Whatman
GF/C Glass Microﬁbre Filters and all bacterial media
components were ordered from Fisher. The QIAPrep
Spin Miniprep Kit was ordered from Qiagen. Tris–HCl
Buﬀer was ordered from Acros Organics. [
3H] PreQ1 was
ordered from American Radiolabeled Chemicals, Inc.
T7 RNA polymerase was isolated from E. coli BL21 cells
containingtheplasmidpBH161accordingtotheprocedure
of Prof. William McCallister, State University of
New York, Brooklyn. The E. coli TGT was isolated with
an amino terminal his-tag as previously described (32).
Synthesis of [
3H]preQ1(Figure4)
The cyano precursor (preQ0, 2) was synthesized according
to the method of Migawa et al. (33) by the condensation
of chloro(formyl)acetonitrile and pyrimidine 1 (33).
Reduction of the cyano precursor with tritium gas gave
the desired radiolabeled substrate preQ1 (3) with a speciﬁc
activity of 500mCi/mmol (34). The tritium reduction was
performed commercially by American Radiolabeled
Compounds Co.
Construction ofpTZvirF
The plasmid pBDG302, containing the virf gene, was
received from Prof. Glenn Bjo ¨ rk (Umea ˚ University,
Sweden). The virf gene was ampliﬁed from the plasmid
by polymerase chain reaction (PCR) under the following
conditions: primers (20pmol each), pBDG302 (500ng),
Mg
2+ (2mM), dNTPs (1mM each), Vent DNA
Figure 3. Nucleotide sequence of virF mRNA. Six UGU sequences are found in the sequence, and are highlighted in red. The sequence of the
virF MH is underlined.
Figure 4. Synthesis of radiolabeled [
3H] preQ1.( A) chloro(formyl)
acetonitrile, NaOAc, H2O, 1008C; (B)
3H2, Pd/C, MeOH, 50psi.
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deionized water. The sample was treated with 30 PCR
cycles of the following sequence: 948C (1min), 508C
(1min), and 728C (2min), followed by a ﬁnal extension at
728C (5min). Following a double restriction enzyme digest
with PstI and EcoRI (40U each, 20-ml reaction) for 1h at
378C, the PCR product and vector were gel-puriﬁed from
Seaplaque agarose with Gelase
TM according to the vendor
protocol. The puriﬁed virf gene was then ligated into
digested pTZ19R
Amp (5:1 volume ratio, 20ml reaction)
following overnight incubation with T4 DNA ligase (2U)
at 178C. The ligated sample (10ml) was transformed into
100ml of Epicurian coli XL2-Blue ultracompetent cells
according to the Stratagene protocol. Cells were grown
overnight at 378C on L-Amp plates (50mg/ml ampicillin).
Individual colonies were isolated, and 3mL 2xTY (16g
Bactotryptone, 10g yeast extract, 5g NaCl/liter of water
with 50mg/ml ampicillin) liquid cultures were inoculated
at 378C with shaking. Plasmid was isolated via miniprep,
and the virf gene sequence was conﬁrmed with DNA
sequencing (University of Michigan DNA Sequencing
Core Facilities).
Invitro transcription
In vitro transcription reactions with pTZvirF were
conducted by ﬁrst linearizing the plasmid at the end
of the virf sequence with the restriction enzyme EcoRI
(40U/100ml DNA, 500ml reaction). The sample was
ethanol precipitated at  208C, and the pellet was re-
suspended in 250ml of deionized water. In vitro 1ml
transcription conditions were as follows: pTZvirF tem-
plate (100ml), transcription buﬀer (4mM Tris–HCl,
pH 8.0; 2mM MgCl2, 0.5mM DTT, 0.1mM spermidine),
NTPs (4mM each), T7 RNA polymerase (2500U),
inorganic pyrophosphatase (2U) and RNase inhibitor
(200U). The reaction was incubated at 378C for  4h. The
reaction was stored at  208C following transcription. Best
results were obtained when the 1ml reaction was prepared
and redistributed into 100ml volumes prior to incubation
at 378C. The MasterAmp
TM High Fidelity RT–PCR Kit
was used according to vendor protocol to generate virf
DNA, which was conﬁrmed with sequence analysis of the
DNA product (Figure 5).
Mfold analysis and synthesis ofvirF MH
Analysisoftheenergeticallyfavorablesecondarystructures
within the virF mRNA sequence was performed using the
biophysical web tool Mfold (M. Zuker, http://bioweb.
pasteur.fr/seqanal/interfaces/mfold-simple.html). Sequences
of  10 nucleotides surrounding either side of the six
possible recognition motifs were analyzed by the web tool,
and the hairpin structure determined to be most favorable
was found between nucleotides 410–433 in the virF
mRNA, which contains the potential recognition sequence
U420G421U422. The RNAture Oligonucleotide Analyzer
web tool was used to predict a Tm of 718C for the virF
minihelix hairpin. (Note: This web tool appears to be no
longer available.) An Expedite
TM Nucleic Acid Synthesis
System was used to synthesize this 24-nucleotide sequence
(50-GGAGUAGUCUUUGUCGACUAUUUU-30) using
the vendor’s protocols for the synthesis of RNA at the
1mmolscale.ThereagentswerefromPerkin–Elmer andthe
RNA amidites were from Glen Research. The extinction
coeﬃcient calculated for this RNA minihelix was
e260=265.3OD/mM.
Generation ofvirF mRNA(G421A)
The single nucleotide mutation of guanine 421 to adenine
in the virF mRNA sequence was generated via
QuikChange site-directed mutagenesis (Stratagene), pro-
ducing the new vector pTZvirF(G421A). The reactions
conditions were as follows: complimentary oligonucleo-
tides with desired mutation (175ng), pTZvirF(wt)
template (800ng), dNTPs (0.25mM) and Vent DNA
polymerase (2U), brought to a ﬁnal volume of 30ml with
deionized water. The sample was treated with 25 PCR
cycles of the following sequence: 948C (30s), 508C (1min),
and 728C (6.5min). The PCR product was then incubated
for 2h at 378C with Dpn I (40U), and addition of
NE Buﬀer 4 was required for proper digestion of wild-type
plasmid. The digested sample (10ml) was transformed into
100ml of Epicurian coli XL2-Blue ultracompetent cells
according to the Stratagene protocol. Cells were grown
overnight at 378C on L-Amp plates (50mg/ml ampicillin).
Individual colonies were isolated, and 3ml 2xTY (16g
bactotryptone, 10g yeast extract, 5g NaCl/liter of water
with 50mg/ml ampicillin) liquid cultures were inoculated
at 378C with shaking. Plasmid was isolated via miniprep,
and the virF mRNA(G421A) mutation was conﬁrmed
with DNA sequencing (University of Michigan DNA
Sequencing Core Facilities).
Kinetic assays
Assays were conducted by monitoring the incorporation
of radiolabeled substrate, [
3H] preQ1, into E. coli
tRNA
Tyr,d G 34ECYMH (50-GGGAGCAGACUdGUAA
AUCUGCUCCC-30) and various virF mRNA substrates.
Samples from in vitro transcriptions were concentrated
Figure 5. Transcription of virF mRNA. (A) In vitro transcription of
virF mRNA visualized with ethidium bromide on a 1% TAE agarose
gel. The single-stranded mRNA ran at  500bp in comparison to the
100-bp DNA ladder (lane 1). Lane 2: virF mRNA from a previous
transcription reaction. Lanes 4 and 5: virF mRNA from replicate
transcription reactions. (B) RT–PCR samples visualized with ethidium
bromide on a 1% TAE agarose gel. RT–PCR was conducted using
extracted mRNA from replicate samples (lanes 2 and 3), electrophor-
esed in comparison to a 100bp DNA ladder (lane 1). Each RNA
sample produced the corresponding 800bp DNA species indicative of
the virf ORF.
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The concentration of virF mRNA was determined with a
Cary UV-Visible Spectrophotometer, where the approx-
imate concentration of a single-stranded RNA sample
A260=1 OD is 40mg/ml and the molecular weight of
virF mRNA is 252g/mmol virF mRNA. In brief, kinetic
assays were set up under the following conditions: RNA
substrate (various concentrations), [
3H] preQ1 (10mM,
296mCi/mmol stock), TGT (100 or 200nM, as speciﬁed),
and HEPES reaction buﬀer (100mM HEPES, pH 7.3;
20mM MgCl2; 5mM DTT) to a ﬁnal volume of 400ml.
All samples were incubated at 378C for purposes of
equilibration before initiating the reaction with the
addition of TGT. Aliquots (70ml) were removed at various
points throughout the reaction and quenched in 3ml of
5% TCA for 1h before ﬁltering on glass-ﬁber ﬁlters.
Each ﬁlter was washed with three volumes of 5% TCA
and a ﬁnal wash of ethanol to dry the ﬁlter. The samples
were analyzed in a scintillation counter (Beckman) for
radioactive decay, where counts were reported in DPM
and later converted to picomoles [
3H] preQ1 by the
following conversion (pmol=DPM 0.00152, for the
[
3H] preQ1 stock with a speciﬁc activity of 296mCi/mmol).
Initial velocities were determined by converting the slopes
of these plots (pmol/min) to units of second
 1, taking into
account the concentration of the enzyme and aliquot size.
The individual data points from each trial were averaged,
and the standard deviation was determined for each
concentration of RNA substrate. The average data points
(with error bars representing their standard deviations)
were plotted. However, all of the individual data points
were ﬁt via non-linear regression to the Michaelis–Menten
equation and the line for that ﬁt is displayed (Figure 6).
All non-linear regression ﬁts with the Michaelis–Menten
equation were determined using Kaleidagraph (Abelbeck
Software).
RESULTS
Construction and invitro transcription of pTZvirF
To provide micromolar quantities of virF mRNA for our
studies, we generated an in vitro transcription clone for
the virF mRNA. The virf gene was subcloned from the
plasmid pBDG302 containing the virf gene (a gift from
Professor Glenn Bjo ¨ rk, Umea ˚ University, Sweden) into a
plasmid suitable for in vitro transcription, generating
pTZvirF. VirF mRNA was synthesized via in vitro run-oﬀ
transcription following digestion with EcoRI, linearizing
pTZvirF at the end of the virf gene sequence. The virF
mRNA was physically characterized on an ethidium
bromide stained, 1.2% formaldehyde agarose gel.RT–
PCR was utilized to generate dsDNA from the in vitro
transcription product using the same oligonucleotide
primers initially designed for subcloning of the virf gene.
Examples of formaldehyde and TAE agarose gels of the
virF mRNA and the dsDNA from the RT–PCR are shown
in Figure 5.
The single-stranded virF mRNA appears to run on the
gel at  500bp in comparison to the dsDNA ladder.
The size of the virf gene is 789bp, and the corresponding
mRNA is 789 nucleotides in length. We hypothesize that
the mRNA is running at a lower ‘apparent’ molecular
weight due to the propensity of mRNA to adopt a variety
of conformations, even in an agarose gel. This would
explain why the observed molecular weight is a little larger
than one half the size of the double-stranded virf DNA.
The RT–PCR product (dsDNA) migrated to the antici-
pated molecular weight for a DNA sample of  800bp.
DNA sequencing of this product matched the virF mRNA
sequence (data not shown).
Kineticanalysis ofE. coli tRNA
Tyr,ECYMH minihelix
withpreQ1
For comparison, Michaelis–Menten kinetic analyses were
conducted with the natural RNA substrate E. coli
tRNA
Tyr (ECY) and the modiﬁed minihelix substrate
dG34ECYMH (the anticodon stem–loop of ECY where
the guanosine at position 34 contains a 20-deoxyribose)
with [
3H] preQ1. It has been shown previously that a
minihelix RNA consisting of the anticodon arm and loop
of a queuine-cognate tRNA is a suﬃcient substrate for
TGT (29). Aliquots were taken at various time points over
a 15min incubation of 100nM E. coli TGT, various
concentrations of ECY (0.05–1.5mM) or dG34ECYMH
(0.05–5mM) and saturating concentrations of [
3H] preQ1.
The kinetic constants determined for the incorporation of
[
3H] preQ1 with ECY and dG34ECYMH are shown in
comparison with the kinetic data for the virF substrates
in Table 1.
Kineticanalysis ofvirF mRNA, virF MHminihelix
with preQ1
Using the same approach described above, Michaelis–
Menten kinetic analyses were conducted with virF mRNA.
Aliquots were taken at various time points over a 1h
incubation of 200nM TGT, various concentrations of virF
mRNA (0.1–10mM), and saturating concentrations of
[
3H] preQ1 (Figure 6A). Higher concentrations of virF
mRNA were tested to obtain an accurate kinetic proﬁle by
characterizing the reaction over a large range of concen-
trations. In addition to characterizing the wild-type virF
mRNA, a virF minihelix RNA (virF MH) corresponding
to the 410–433 hairpin sequence (underlined in Figure 3)
as well as a full-length virF mRNA mutant (G421A) were
studied. The kinetic analyses were performed with 100nM
E. coli TGT, various concentrations of virF MH
(0.1–10mM) and saturating concentrations of [
3H] preQ1
(Figure 6B). The full-length virF mRNA(G421A) was
incubated under the same conditions as the wild-type
mRNA, but only at concentrations corresponding to KM
and 5xKM, as determined from the kinetic constants of
virF mRNA(wt) (Table 1). A ‘no RNA’ control was also
included to determine the background level of radio-
activity present in the samples (Figure 6C). The data were
ﬁt by non-linear regression.
Both the full-length virF mRNA(wt) and the virF
minihelix exhibited RNA concentration-dependent
incorporation of [
3H] preQ1 over time, and the
Michaelis–Menten equation provided a good ﬁt for the
data. The full-length virF mRNA(G421A), which is
Nucleic Acids Research, 2007, Vol. 35, No. 14 4909full-length mRNA with a single nucleotide mutation
at guanine 421, was analyzed at both 2mM(  KM) and
10mM(  5 KM) mRNA. The virF mRNA(G421A)
mutant showed no detectable activity greater than the
‘no RNA’ control (Figure 6C). The kinetic constants
determined for the virF mRNA substrates are shown in
Table 1.
Both the virF mRNA and virF MH have KM values in
the low micromolar range, even though kcat and kcat/KM
for both is lower than the corresponding values for the
ECY substrates.
DISCUSSION
VirF is a critical transcriptional regulator responsible for
activating virulence genes in Shigella ﬂexneri. Durand and
colleagues (35) demonstrated the involvement of TGT in
modulating the translation of VirF via the observation
AB
C
Figure 6. Kinetic characterization of virF mRNA substrates with E. coli TGT and [
3H] preQ1.( A) and (B) The individual data points were ﬁt to the
Michaelis–Menten equation by non-linear regression, and the average data points (with error bars representing the standard deviations of the
averages) for each concentration of RNA substrate are depicted. The study was performed with duplicate kinetic trials at saturating concentrations of
[
3H] preQ1. The inset in B shows the structure of the RNA minihelix corresponding to bases 410–433 of the virF mRNA. (C) The comparison of
radioactive substrate incorporated over time in virF mRNA(wt) (blue, squares and diamonds), virF mRNA(G421A) (green, crosses and triangles), and
a no RNA control (red, circles), ﬁt by linear regression. Each virF mRNA substrate was analyzed at two concentrations: 2mM (squares and crosses)
and 10mM (diamonds and triangles). The average of duplicate trials is shown.
Table 1. RNA kinetic parameters with E. coli htTGT(wt) and [
3H]
preQ1at pH 7.3
KM (mM) kcat (10
 4 s





a 40 (2) 250 (40)
dG34ECYMH 0.26 (0.07) 70 (5) 270 (60)
virF mRNA 1.8 (0.4) 1.1 (0.1) 0.60 (0.1)
virF MH 0.87 (0.3) 3.3 (0.3) 3.8 (1)
aStandard errors are in parentheses.
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tgt gene (termed vacC) showed decreased virulence. VirF
protein levels were dramatically lower in the mutant as
compared to wild-type, but the virF mRNA levels showed
no detectable diﬀerence from wild-type Shigella. The lack
of VirF protein resulted in a reduction of all downstream
virulence gene expression, and thus exhibited a less
virulent phenotype than that of the wild-type bacterium.
When transformed with a plasmid encoding the Shigella
tgt gene, both VirF translation and virulence were
restored. It had previously been shown that the presence
of modiﬁed nucleosides enhances translation (36,37).
However, other studies have shown that growth rate and
protein translation as a whole are not directly aﬀected by a
lack of queuine-modiﬁed tRNA (38). While this interest-
ing correlation between VirF translation and TGT activity
has been known for some time, yet the exact role TGT
plays in the translation of this primary virulence factor
remains unclear.
Our laboratory has previously demonstrated that TGT
can modify substrates with more unusual structures than a
canonical tRNA fold. We reported that a dimeric form of
the ECY serves as a substrate for TGT, with a slightly
higher KM and identical kcat, relative to the normal tRNA
(31). It had previously been shown from NMR studies
that the anticodon arms of the dimer subunits were intact
and pointing away from the center of the dimer (39).
Those studies demonstrate that TGT can recognize a
minihelix containing the requisite U-G-U sequence even
in the context of a larger RNA structure. TGT is not the
ﬁrst tRNA modiﬁcation enzyme to demonstrate recogni-
tion of alternative RNA structures. Gu and coworkers
(24) have shown that, in vitro, the modiﬁcation enzyme
tRNA (m
5U54)-methyltransferase will methylate 16S
ribosomal RNA from E. coli in addition to its physiolo-
gical tRNA substrate, although they found no evidence
for this occurring in vivo. The enzyme pseudouridine
synthase catalyzes the isomerization of speciﬁc uridines
to the modiﬁed nucleoside c. A single pseudouridine
synthase has been shown to have ‘dual speciﬁcity’,
recognizing and modifying both tRNA and snRNA
(40–42). Ofengand and colleagues (43,44) have also
characterized a critical pseudouridine synthase responsible
for site-speciﬁc modiﬁcation with pseudouridine in vivo for
both tRNA and 23SrRNA in E. coli. Such precedence
for tRNA modiﬁcation enzymes to recognize and modify
other RNA species in vitro and in vivo, suggests that virF
mRNA modiﬁcation mediated by TGT may also occur.
As a ﬁrst step to probe for this possibility, we examined
the virF mRNA sequence for the presence of a U-G-U
sequence in a TGT recognition motif. Of the six U-G-U
sequences in the virF mRNA, the one involving bases
410–433 (Figure 3) was predicted by Mfold analysis to be
able to fold into a hairpin structure possibly suitable for
recognition by TGT.
Incubation of virF mRNA with E. coli TGT and
radiolabeled preQ1 revealed that the virF mRNA is indeed
a substrate for TGT in vitro. The kinetic parameters (KM,
kcat; Table 1) for virF mRNA were determined from a
Michaelis–Menten analysis (Figure 6A). The virF mRNA
substrates exhibit the same trend in kinetic parameters as
the ECY substrates, where the minihelix substrates
(dG34ECYMH and virF MH) have slightly higher values
for both KM and kcat/KM with respect to the correspond-
ing full-length RNA substrates (Table 1). The values of
KM for both ECY and virF mRNA are very similar, both
in the low micromolar range. This is encouraging
considering the size and structural diﬀerence between the
two substrates, where ECY is  80 nucleotides in length
with a very well-deﬁned tertiary structure common to
tRNA and the virF mRNA is ca. 800 nucleotides in length
and presumably does not have a compact tertiary
structure. The Michaelis–Menten plot for the virF
mRNA (Figure 6A) ﬁts to a single KM, consistent with a
single site of modiﬁcation within the virF mRNA. The kcat
for the virF mRNA is   40-fold lower than that for tRNA.
It has previously been shown that altering the position of
the U-G-U sequence within the minihelix loop of cognate
tRNAs is correlated with a reduction in activity (45).
All of the biochemical and structural data previously
reported is consistent with a covalent intermediate, via
Asp264, in the TGT reaction (32,46–48). The hairpin loop
of the ECY substrate contains seven nucleotides, whereas
the hairpin in the virF mRNA substrate contains only six
nucleotides in the loop. This diﬀerence in loop length may
result in a suboptimal orientation of the guanosine ribose
in the U420-G421-U422 loop in the virF mRNA, making
nucleophilic attack by Asp264 less likely. This diﬀerence
in loop length and orientation could account for the
reduced kcat that we have observed for the virF mRNA
substrates.
Our analysis of the virF mRNA sequence predicts that
there should be a single site of modiﬁcation, guanine 421.
We have taken two approaches to investigate this. In our
ﬁrst approach, a virF MH corresponding to the predicted
hairpin structure within the native virF mRNA sequence
(bases 410–433), was chemically synthesized (Figure 6B).
The stem consists of nine base pairs, where the ﬁrst four
nucleotides in the stem are uridine residues forming
wobble pair interactions with three guanines and one
Watson–Crick pair with an adenosine. At ﬁrst glance,
the stability of a minihelix with three G-U wobble pairs
might be questionable; however, in the context of the
virF mRNA, the ends of the helix may be held in close
proximity by other intramolecular interactions.
Additionally, the virF MH by itself has a predicted
melting temperature of 718C, indicating the structure
should be stable at physiological and assay temperatures.
The virF MH is a substrate for TGT in vitro. The KM
values for both the full-length virF mRNA and virF MH
(1.8 and 0.87mM, respectively; Table 1) are very similar,
suggesting that the minihelix structure is likely a
predominant conformation in the virF mRNA.
Although the recognition of the virF minihelix by TGT
is consistent with the virF mRNA serving as a substrate
for TGT, it does not provide conclusive evidence that
guanine 421 is the site of modiﬁcation in the virF mRNA.
There are six UGU sequences within the virF mRNA that
are possible recognition sites for TGT. Therefore, our
second approach was to construct the point mutation,
G421A, in the full-length virF mRNA to demonstrate the
importance of guanine 421. The virF mRNA(G421A)
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diﬀerent concentrations of RNA (Figure 6C), indicating
that G421 is indeed essential for recognition by TGT. Had
a second exchangeable guanine existed in the sequence,
we would have expected to see a decreased or possibly
even unchanged activity of the mRNA. The relationship
between the ‘no RNA’ negative control and the virF
mRNA(G421A) indicates that guanine 421 is the only
exchangeable nucleotide in the virF mRNA sequence (at
least within the concentration ranges tested), and that the
kinetic parameters observed for virF mRNA(wt) are due
to speciﬁc recognition by TGT and could not be attributed
to non-speciﬁc interactions with this large nucleic acid
molecule. It should be noted that, under the conditions of
the assay (Figure 6C), it appears that the enzyme is
undergoing a limited number of turnovers. Two factors
may be contributing to this. The ﬁrst is that our
calculations of kinetic parameters assume 100% active
enzyme, which is almost certainly an over-estimate. The
active enzyme concentration may be as much as 2-fold
lower as recent studies suggest that the eubacterial TGT
may exist as a homodimer with ‘half-of-sites’ reactivity
(49). This would eﬀectively double the turnovers per active
site. Second, the oﬀ-rate for the modiﬁed mRNA may be
suﬃciently slower (relative to that for tRNA) such that the
turnover rate may indeed be signiﬁcantly slowed under
these conditions. It remains to be seen if these observa-
tions hold under in vivo conditions.
From the results presented herein, it is clear that the
virF mRNA does act as a substrate for the eubacterial
TGT in vitro. Although there are six possible UGU
recognition motifs, both the mutagenesis and virF mRNA
minihelix studies are consistent with G421 serving as the
sole site of modiﬁcation within the mRNA. With a KM
value in the low micromolar range, it is very possible that
the modiﬁcation of virF mRNA may be biologically
relevant (e.g. may occur in vivo). These results provide the
ﬁrst ‘proof of principle’ evidence that post-transcriptional
RNA modiﬁcation may regulate mRNA function, as it
has long been recognized to do for tRNA. The recent
work characterizing the preQ1 riboswitch revealed that it
is a fairly simple hairpin structure (the simplest riboswitch
structure characterized to date) (23). Such a simple
structure could feasibly occur in the coding region of an
mRNA species. In fact, the TGT modiﬁcation site that we
have discovered in the virF mRNA is predicted to occur in
a simple hairpin structural motif. Base modiﬁcation in a
hairpin structure in the coding sequence of virF mRNA
could induce a similar structural switch as seen in the
preQ1 riboswitch and thereby inﬂuence translation of
VirF. Studies to determine the physiological signiﬁcance
of the virF mRNA modiﬁcation by TGT that we have
observed in vitro are currently in progress.
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